Stocklytics Platform
Asset logo for symbol FULC
Fulcrum Therapeutics
FULC64
$4.54arrow_drop_down2.77%-$0.12
Penny Stock
Asset logo for symbol FULC
FULC64

$4.54

arrow_drop_down2.77%

Performance History

Chart placeholder
Key Stats
Open$4.70
Prev. Close$4.68
EPS-0.29
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$245.42M
PE Ratio-
LOWHIGH
Day Range4.37
5.12
52 Week Range2.86
13.70
Ratios
EPS-0.29

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

About Fulcrum Therapeutics (FULC)

Fulcrum Therapeutics Inc (FULC) is a biopharmaceutical company focused on developing and commercializing therapies for genetically defined diseases. The company's mission is to accelerate the development of targeted therapies to improve the lives of patients with serious and rare diseases. Fulcrum Therapeutics is driven by the potential of its unique product platform, which is designed to identify and target the root cause of a disease at the gene level.
Fulcrum Therapeutics has a strong commitment to research and development, with a focus on harnessing the power of gene regulation to develop transformative therapies. The company's lead product candidate, FTX-6058, is currently in clinical development for the treatment of sickle cell disease. Sickle cell disease is a genetic disorder that affects the shape and function of red blood cells, leading to various complications.
Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Alexander C. Sapir
Headquarters
Cambridge
Employees
89
Exchange
NASDAQ
add Fulcrum Therapeutics  to watchlist

Keep an eye on Fulcrum Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is Fulcrum Therapeutics 's (FULC) price per share?

The current price per share for Fulcrum Therapeutics (FULC) is $4.54. The stock has seen a price change of -$0.13 recently, indicating a -2.78% change. This reflects the stock's recent market performance and investor sentiment.
help

What is the 52-week high and low for Fulcrum Therapeutics (FULC)?

For Fulcrum Therapeutics (FULC), the 52-week high is $13.7, which is 201.76% from the current price. The 52-week low is $2.86, the current price is 58.46% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help

Is Fulcrum Therapeutics (FULC) a growth stock?

Fulcrum Therapeutics (FULC) has shown an average price growth of -5.34% over the past three years. It has received a score of 11 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Fulcrum Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help

What is Fulcrum Therapeutics (FULC) stock price performance year to date (YTD)?

As of the latest data, Fulcrum Therapeutics (FULC) has a year-to-date price change of -37.03%. Over the past month, the stock has experienced a price change of 31.98%. Over the last three months, the change has been 41.87%. Over the past six months, the figure is -28.39%. Looking at a longer horizon, the five-year price change stands at -72.45%.
help

Is Fulcrum Therapeutics (FULC) a profitable company?

Fulcrum Therapeutics (FULC) has a net income of -$97.34M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 65.62% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $2.8M, although specific revenue growth data is currently not available. The gross profit is $2.8M. Operating income is noted at -$110.66M. Furthermore, the EBITDA is -$30.88M.
help

What is the market capitalization of Fulcrum Therapeutics (FULC)?

Fulcrum Therapeutics (FULC) has a market capitalization of $245.42M. The average daily trading volume is 4.61, indicating the stock's liquidity and investor engagement.

Take Your Investments to a Whole New Level